Call for action: expanding global access to hereditary cancer genetic testing

Brittany Bychkovsky; Huma Q. Rana; Foluso Ademuyiwa; Jennifer Plichta; Karen Anderson; Angélica Nogueira-Rodrigues; Cesar A. Santa-Maria; Lan G. Coffman; Carol Marquez; Arunangshu Das; Alphonse Taghian; Diane R. Koeller; Renata L. Sandoval; Ben Ho Park; Don S. Dizon

doi:10.1016/S1470-2045(22)00378-3

Call for action: expanding global access to hereditary cancer genetic testing

Brittany Bychkovsky, Huma Q. Rana, Foluso Ademuyiwa, Jennifer Plichta, Karen Anderson, Angélica Nogueira-Rodrigues, Cesar A. Santa-Maria, Lan G. Coffman, Carol Marquez, Arunangshu Das, Alphonse Taghian, Diane R. Koeller, Renata L. Sandoval, Ben Ho Park, Don S. Dizon

Research output: Contribution to journal › Comment/debate

8 Scopus citations

Original language	English
Pages (from-to)	1124-1126
Number of pages	3
Journal	The Lancet Oncology
Volume	23
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(22)00378-3
State	Published - Sep 2022

Access to Document

10.1016/S1470-2045(22)00378-3

Cite this

Bychkovsky, B., Rana, H. Q., Ademuyiwa, F., Plichta, J., Anderson, K., Nogueira-Rodrigues, A., Santa-Maria, C. A., Coffman, L. G., Marquez, C., Das, A., Taghian, A., Koeller, D. R., Sandoval, R. L., Park, B. H., & Dizon, D. S. (2022). Call for action: expanding global access to hereditary cancer genetic testing. The Lancet Oncology, 23(9), 1124-1126. https://doi.org/10.1016/S1470-2045(22)00378-3

@article{9c12a206d9854772ba0aa6e8e898e978,

title = "Call for action: expanding global access to hereditary cancer genetic testing",

author = "Brittany Bychkovsky and Rana, {Huma Q.} and Foluso Ademuyiwa and Jennifer Plichta and Karen Anderson and Ang{\'e}lica Nogueira-Rodrigues and Santa-Maria, {Cesar A.} and Coffman, {Lan G.} and Carol Marquez and Arunangshu Das and Alphonse Taghian and Koeller, {Diane R.} and Sandoval, {Renata L.} and Park, {Ben Ho} and Dizon, {Don S.}",

note = "Funding Information: DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD, Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors declare no competing interests. ",

year = "2022",

month = sep,

doi = "10.1016/S1470-2045(22)00378-3",

language = "English",

volume = "23",

pages = "1124--1126",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "9",

}

Bychkovsky, B, Rana, HQ, Ademuyiwa, F, Plichta, J, Anderson, K, Nogueira-Rodrigues, A, Santa-Maria, CA, Coffman, LG, Marquez, C, Das, A, Taghian, A, Koeller, DR, Sandoval, RL, Park, BH & Dizon, DS 2022, 'Call for action: expanding global access to hereditary cancer genetic testing', The Lancet Oncology, vol. 23, no. 9, pp. 1124-1126. https://doi.org/10.1016/S1470-2045(22)00378-3

TY - JOUR

T1 - Call for action

T2 - expanding global access to hereditary cancer genetic testing

AU - Bychkovsky, Brittany

AU - Rana, Huma Q.

AU - Ademuyiwa, Foluso

AU - Plichta, Jennifer

AU - Anderson, Karen

AU - Nogueira-Rodrigues, Angélica

AU - Santa-Maria, Cesar A.

AU - Coffman, Lan G.

AU - Marquez, Carol

AU - Das, Arunangshu

AU - Taghian, Alphonse

AU - Koeller, Diane R.

AU - Sandoval, Renata L.

AU - Park, Ben Ho

AU - Dizon, Don S.

N1 - Funding Information: DSD reports institutional support from Bristol Myers Squibb and Pfizer; and consults for AstraZeneca, Clovis, Regeneron, and Pfizer. BHP receives consulting and advisory board fees from Jackson Labs, EQRx, Sermonix, Hologics, Guardant Health, and Celcuity; has research contracts with GE Healthcare and Eli Lilly; and is entitled to royalties on sales of products licensed by Horizon Discovery and Johns Hopkins University. JP reports funding from the Color Foundation unrelated to this work. CAS-M reports funding from AstraZeneca, Pfizer, Bristol Myers Squibb, and Tesaro/GSK; and is on the advisory board of Seattle Genetics. AT reports royalties for breast cancer chapters written for an online UpToDate book; payment for expert testimony; plans to patent a device to be used in lymphoedema patients; non-paid advisory board service for Puretech; and received Sozo bioimpedance equipment for an investigator-led study on lymphoedema. AN-R reports honoraria and support for attending meetings and travel from Roche, MSD, Astra Zeneca, and Eisai; and leadership roles with the Brazilian Group of Gynecology Oncology and Brazilian Society of Medical Oncology. All other authors declare no competing interests.

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85137113569&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00378-3

DO - 10.1016/S1470-2045(22)00378-3

M3 - Comment/debate

C2 - 36055301

AN - SCOPUS:85137113569

SN - 1470-2045

VL - 23

SP - 1124

EP - 1126

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -

Call for action: expanding global access to hereditary cancer genetic testing

Access to Document

Other files and links

Cite this